See more : Perfect Group Corp., Ltd (603059.SS) Income Statement Analysis – Financial Results
Complete financial analysis of United Therapeutics Corporation (UTHR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of United Therapeutics Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- West Canyon Energy Corp. (WCYN) Income Statement Analysis – Financial Results
- Space-Communication Ltd (SPMMF) Income Statement Analysis – Financial Results
- Visionary Holdings Inc. (GV) Income Statement Analysis – Financial Results
- Lundin Mining Corporation (LUMI.ST) Income Statement Analysis – Financial Results
- Veji Holdings Ltd. (VEJI.CN) Income Statement Analysis – Financial Results
United Therapeutics Corporation (UTHR)
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.33B | 1.94B | 1.69B | 1.48B | 1.45B | 1.63B | 1.73B | 1.60B | 1.47B | 1.29B | 1.12B | 916.08M | 743.18M | 603.83M | 369.85M | 281.50M | 210.94M | 159.63M | 115.92M | 73.59M | 53.34M | 30.12M | 5.73M | 2.05M | 400.00K | 100.00K |
| Cost of Revenue | 257.50M | 146.70M | 122.50M | 108.10M | 117.60M | 198.70M | 105.70M | 72.70M | 69.04M | 125.88M | 131.13M | 119.30M | 88.90M | 73.47M | 45.32M | 30.07M | 22.26M | 17.03M | 12.32M | 8.25M | 6.78M | 5.46M | 3.14M | 1.71M | 1.40M | 0.00 |
| Gross Profit | 2.07B | 1.79B | 1.56B | 1.38B | 1.33B | 1.43B | 1.62B | 1.53B | 1.40B | 1.16B | 985.86M | 796.78M | 654.28M | 530.37M | 324.53M | 251.43M | 188.68M | 142.60M | 103.60M | 65.34M | 46.56M | 24.66M | 2.59M | 343.47K | -1.00M | 100.00K |
| Gross Profit Ratio | 88.94% | 92.42% | 92.73% | 92.71% | 91.88% | 87.79% | 93.87% | 95.45% | 95.29% | 90.23% | 88.26% | 86.98% | 88.04% | 87.83% | 87.75% | 89.32% | 89.45% | 89.33% | 89.38% | 88.79% | 87.28% | 81.89% | 45.27% | 16.76% | -250.00% | 100.00% |
| Research & Development | 408.00M | 322.90M | 540.10M | 357.70M | 1.18B | 357.90M | 264.60M | 147.60M | 245.10M | 242.55M | 299.35M | 173.39M | 180.02M | 166.76M | 122.19M | 239.18M | 83.35M | 57.57M | 36.05M | 30.60M | 35.42M | 26.78M | 32.59M | 70.19M | 30.70M | 11.00M |
| General & Administrative | 395.30M | 416.20M | 402.60M | 369.00M | 275.50M | 206.70M | 265.80M | 232.20M | 358.32M | 299.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.44M | 16.94M | 11.74M | 5.00M | 0.00 |
| Selling & Marketing | 81.80M | 70.80M | 64.40M | 54.90M | 60.70M | 59.10M | 64.30M | 84.60M | 94.30M | 82.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.45M | 3.38B | 0.00 | 0.00 | 0.00 |
| SG&A | 477.10M | 487.00M | 467.00M | 423.90M | 336.20M | 265.80M | 330.10M | 316.80M | 452.61M | 381.29M | 394.01M | 201.75M | 156.48M | 199.60M | 176.34M | 94.31M | 99.03M | 54.03M | 24.66M | 21.53M | 22.67M | 15.89M | 16.94M | 11.74M | 5.00M | 2.40M |
| Other Expenses | 0.00 | -40.20M | 42.20M | 49.30M | 22.60M | -7.70M | 13.20M | 2.40M | 157.00K | 3.97M | 635.00K | 31.87M | 156.48M | 199.60M | 176.34M | 94.31M | 99.03M | 56.05M | 24.66M | 21.53M | 22.67M | 15.89M | 0.00 | -79.74K | -1.30M | 2.40M |
| Operating Expenses | 885.10M | 809.90M | 1.01B | 781.60M | 1.52B | 623.70M | 594.70M | 464.40M | 697.71M | 623.84M | 693.36M | 375.13M | 336.50M | 366.36M | 298.53M | 333.49M | 182.38M | 113.62M | 60.71M | 52.13M | 58.08M | 42.67M | 49.53M | 81.84M | 34.40M | 13.40M |
| Cost & Expenses | 1.14B | 956.60M | 1.13B | 889.70M | 1.64B | 822.40M | 700.40M | 537.10M | 766.75M | 749.72M | 824.49M | 494.43M | 425.40M | 439.83M | 343.85M | 363.55M | 204.64M | 130.65M | 73.02M | 60.38M | 64.87M | 48.12M | 52.67M | 83.55M | 35.80M | 13.40M |
| Interest Income | 162.70M | 45.20M | 16.70M | 28.60M | 44.20M | 28.60M | 10.90M | 3.50M | 0.00 | 0.00 | 3.83M | 3.94M | 3.45M | 2.94M | 5.15M | 11.03M | 13.60M | 10.70M | 5.36M | 2.99M | 2.44M | 4.95M | 10.02M | 10.69M | 0.00 | 0.00 |
| Interest Expense | 59.30M | 32.40M | 18.60M | 23.50M | 44.20M | 13.90M | 9.00M | 3.90M | 4.74M | 17.59M | 18.06M | 16.64M | 21.37M | 19.71M | 12.88M | 16.00K | 2.18M | 482.00K | 29.00K | 4.00K | 112.00K | 117.00K | 172.72K | 120.04K | 0.00 | 0.00 |
| Depreciation & Amortization | 53.20M | 51.30M | 49.90M | 49.90M | 45.90M | 35.90M | 31.00M | 31.60M | 32.92M | 32.25M | 31.26M | 27.15M | 20.54M | 17.92M | 11.39M | 4.54M | 957.00K | 1.46M | 2.41M | 2.28M | 2.33M | 3.14M | 3.51M | -79.74K | -1.30M | -500.00K |
| EBITDA | 1.39B | 1.04B | 736.80M | 646.30M | -74.90M | 838.40M | 1.05B | 1.09B | 1.08B | 575.02M | 323.76M | 484.46M | 341.02M | 185.47M | 43.04M | -67.75M | 22.19M | 28.98M | 50.09M | 17.83M | -9.20M | -14.87M | -43.42M | -81.58M | -36.66M | -13.80M |
| EBITDA Ratio | 59.58% | 50.85% | 36.48% | 45.27% | -8.34% | 50.76% | 60.17% | 66.56% | 47.70% | 42.12% | 26.59% | 52.88% | 43.21% | 27.62% | 8.38% | -25.31% | 3.83% | 19.59% | 39.04% | 20.98% | -17.60% | -15.25% | -754.18% | -3,752.55% | -9,200.00% | -13,800.00% |
| Operating Income | 1.18B | 979.70M | 555.90M | 593.60M | -187.60M | 805.40M | 814.90M | 1.06B | 699.02M | 538.80M | 292.50M | 421.65M | 317.78M | 164.01M | 26.00M | -82.06M | 6.30M | 28.98M | 42.89M | 13.21M | -11.53M | -18.00M | -46.94M | -81.50M | -35.40M | -13.30M |
| Operating Income Ratio | 50.91% | 50.60% | 32.98% | 40.02% | -12.95% | 49.48% | 47.23% | 66.41% | 47.69% | 41.82% | 26.19% | 46.03% | 42.76% | 27.16% | 7.03% | -29.15% | 2.99% | 18.16% | 37.00% | 17.95% | -21.61% | -59.77% | -818.93% | -3,977.08% | -8,850.00% | -13,300.00% |
| Total Other Income/Expenses | 89.40M | -29.10M | 38.00M | 45.30M | 22.60M | -46.50M | -45.40M | -1.50M | 345.42M | -13.60M | -13.60M | 19.03M | -18.67M | -16.17M | -7.23M | 9.76M | 10.28M | 10.93M | 4.63M | 2.24M | 1.56M | -5.65M | 9.65M | -4.68M | 63.50K | 546.20K |
| Income Before Tax | 1.27B | 950.60M | 593.90M | 638.90M | -165.00M | 758.90M | 769.50M | 1.06B | 1.04B | 525.18M | 278.90M | 440.67M | 299.12M | 147.84M | 18.77M | -72.30M | 16.58M | 39.91M | 47.52M | 15.45M | -9.97M | -23.65M | -37.29M | -86.18M | -35.30M | -12.80M |
| Income Before Tax Ratio | 54.75% | 49.09% | 35.24% | 43.07% | -11.39% | 46.62% | 44.60% | 66.31% | 71.26% | 40.76% | 24.97% | 48.10% | 40.25% | 24.48% | 5.07% | -25.68% | 7.86% | 25.00% | 41.00% | 20.99% | -18.69% | -78.52% | -650.55% | -4,205.51% | -8,825.00% | -12,800.00% |
| Income Tax Expense | 289.50M | 223.30M | 118.10M | 124.10M | -60.50M | 169.70M | 351.60M | 346.50M | 392.80M | 185.11M | 104.34M | 136.23M | 81.87M | 41.92M | -695.00K | -29.51M | -3.28M | -34.06M | -17.49M | -3.03M | -2.51M | 5.44M | -9.65M | -5.89M | -1.90M | 0.00 |
| Net Income | 984.80M | 727.30M | 475.80M | 514.80M | -104.50M | 589.20M | 417.90M | 713.70M | 651.64M | 340.07M | 174.56M | 304.44M | 217.87M | 105.92M | 19.46M | -42.79M | 19.86M | 73.97M | 65.02M | 15.45M | -9.97M | -23.65M | -37.29M | -75.61M | -33.50M | -12.80M |
| Net Income Ratio | 42.31% | 37.56% | 28.23% | 34.71% | -7.21% | 36.20% | 24.22% | 44.64% | 44.46% | 26.39% | 15.63% | 33.23% | 29.32% | 17.54% | 5.26% | -15.20% | 9.41% | 46.33% | 56.09% | 20.99% | -18.69% | -78.52% | -650.55% | -3,689.55% | -8,375.00% | -12,800.00% |
| EPS | 21.04 | 15.98 | 10.60 | 11.65 | -2.39 | 13.54 | 9.50 | 16.29 | 14.17 | 7.06 | 3.49 | 5.84 | 3.81 | 1.89 | 0.37 | -0.93 | 0.47 | 1.61 | 1.43 | 0.36 | -0.24 | -0.57 | -0.92 | -1.97 | -1.26 | -0.77 |
| EPS Diluted | 19.81 | 15.00 | 10.06 | 11.54 | -2.39 | 13.39 | 9.31 | 15.25 | 12.72 | 6.28 | 3.28 | 5.71 | 3.67 | 1.78 | 0.35 | -0.93 | 0.44 | 1.53 | 1.29 | 0.33 | -0.24 | -0.57 | -0.92 | -1.97 | -1.26 | -0.77 |
| Weighted Avg Shares Out | 46.80M | 45.50M | 44.90M | 44.20M | 43.80M | 43.50M | 44.00M | 43.80M | 46.00M | 48.18M | 50.08M | 52.09M | 57.16M | 56.14M | 53.31M | 45.80M | 42.45M | 46.02M | 45.65M | 43.45M | 42.27M | 41.29M | 40.57M | 38.47M | 26.69M | 16.64M |
| Weighted Avg Shares Out (Dil) | 49.70M | 48.50M | 47.30M | 44.60M | 43.80M | 44.00M | 44.90M | 46.80M | 51.22M | 54.16M | 53.23M | 53.28M | 59.40M | 59.52M | 56.13M | 45.80M | 44.90M | 48.28M | 50.41M | 46.70M | 42.27M | 41.29M | 40.57M | 38.47M | 26.69M | 16.64M |
United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates
United Therapeutics Corporation Reports Third Quarter 2024 Financial Results
Curious about United Therapeutics (UTHR) Q3 Performance? Explore Wall Street Estimates for Key Metrics
United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting
United Therapeutics (UTHR) Up 9.9% Since Last Earnings Report: Can It Continue?
United Therapeutics Shares Thrive
United Therapeutics: Economics Support Compounding Ability
Stock Market Fades Badly As Dow Jones Index Turns Back At This Critical Level
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
Source: https://incomestatements.info
Category: Stock Reports